Skip to main content

Sylvie Grégoire, James Mullen

Sylvie Grégoire has been elected to the board of PerkinElmer. She has more than 30 years of industry experience and most recently served for seven years as the president of human genetic therapies at Shire. Prior to that, she was executive chairwoman of IDM Pharma, currently a subsidiary of Takeda Pharmaceuticals. She also has been president and CEO of GlycoFi and held leadership, regulatory, and clinical research positions at Biogen and Merck. Grégoire is currently a board member of Galenica.

The firm also said that James Mullen has decided not to stand for re-election as a director of the company at the annual meeting of shareholders to be held on April 28, 2015.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.